Inovio Pharmaceuticals, Inc. (INO) — Financial statements
Income statement, balance sheet, and cash flow for Inovio Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.07↓70.0% | 0.22↓73.8% | 0.83↓91.9% | 10↑478.2% | 2 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.07↓70.0% | 0.22↓73.8% | 0.83↓91.9% | 10↑478.2% | 2 | |
| Operating Expenses | ||||||
| R&D Expenses | 54↓28.3% | 76↓12.8% | 87↓53.8% | 188↓24.7% | 249 | |
| General & Administrative Expenses | 33↓11.7% | 37↓22.2% | 48↓47.2% | 90↑67.8% | 54 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 33↓11.7% | 37↓22.2% | 48↓47.2% | 90↑67.8% | 54 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 11 | 0.00 | 0.00 | |
| Operating Expenses | 87↓22.8% | 113↓22.2% | 145↓47.9% | 278↓8.3% | 303 | |
| Total Costs & Expenses | 87↓22.8% | 113↓22.2% | 145↓47.9% | 278↓8.3% | 303 | |
| Operating Results | ||||||
| Operating Income | -87↑22.8% | -112↑21.9% | -144↑46.2% | -268↑11.2% | -301 | |
| Depreciation & Amortization | 3↓4.5% | 3↓10.7% | 4↓36.3% | 5↑16.2% | 5 | |
| EBITDA | -82↑21.2% | -104↑20.3% | -130↑51.9% | -271↑8.7% | -297 | |
| EBIT | -85↑20.7% | -107↑20.0% | -134↑51.6% | -276↑8.3% | -301 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓47.3% | 5↓33.6% | 7↑95.9% | 4↑147.3% | 1 | |
| Interest Income | 2↓49.2% | 5↓41.4% | 8↑70.1% | 5↑42.2% | 3 | |
| Interest Expense | 0.00↓100.0% | 0.18↓85.5% | 1↓2.5% | 1↓35.2% | 2 | |
| Non-Operating Income | -2↑64.8% | -5↑47.0% | -10↓213.8% | 9↑12515.4% | 0.07 | |
| Other Income / Expenses | 2↓63.5% | 5↓41.7% | 9↑172.1% | -12↓401.7% | -2 | |
| Income Before Tax | -85↑20.8% | -107↑20.6% | -135↑51.7% | -280↑7.9% | -304 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -85↑20.8% | -107↑20.6% | -135↑51.7% | -280↑7.9% | -304 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -85↑20.8% | -107↑20.6% | -135↑51.7% | -280↑7.9% | -304 | |
| Bottom-Line Net Income | -85↑20.8% | -107↑20.6% | -135↑51.7% | -280↑7.9% | -304 | |
| EPS (Basic) | -1.81↑54.2% | -3.95↑35.1% | -6.09↑56.7% | -14.07↓890.8% | -1.42 | |
| EPS (Diluted) | -1.81↑54.2% | -3.95↑35.1% | -6.09↑56.7% | -14.07↓890.8% | -1.42 | |
| Weighted Average Shares | 469↑1626.2% | 27↑22.5% | 22↑11.5% | 20↓90.7% | 215 | |
| Weighted Average Diluted Shares | 469↑1626.2% | 27↑22.5% | 22↑11.5% | 20↓90.7% | 215 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.